<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prognosis of heart failure with mildly reduced ejection fraction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prognosis of heart failure with mildly reduced ejection fraction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prognosis of heart failure with mildly reduced ejection fraction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barry A Borlaug, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donna Mancini, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Theo E Meyer, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4015394928"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical syndrome of heart failure (HF) can develop in patients with low, mildly decreased, or normal left ventricular ejection fraction (LVEF).</p><p>This topic will discuss the details of treatment and prognosis in patients with HF and mildly reduced ejection fraction (HFmrEF, LVEF 41 to 49 percent), formerly referred to as HF with mid-range ejection fraction [<a href="#rid1">1</a>].</p><p>In patients with HFmrEF, the clinical presentation and evaluation are the same as for patients with HF with reduced ejection fraction and are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Clinical presentation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a>.)</p><p></p><p>Management strategies for acute HF are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">"Treatment of acute decompensated heart failure: Specific therapies"</a> and  <a class="medical medical_review" href="/z/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.)</p><p class="headingAnchor" id="H2773580257"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure (HF)</strong> – HF is a clinical diagnosis based upon identification of symptoms (eg, dyspnea and fatigue) caused by impairment of ventricular filling or ejection of blood  (<a class="graphic graphic_table graphicRef55866" href="/z/d/graphic/55866.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. The diagnosis of the clinical syndrome of HF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Definition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure with mildly reduced LVEF (HFmrEF) </strong>–<strong> </strong>Consistent with the professional guidelines, HFmrEF (formerly referred to as HF with mid-range ejection fraction) is defined as the presence of clinical HF and an LVEF of 41 to 49 percent, although the precise limits of LVEF for this condition vary among major society guidelines [<a href="#rid1">1,2</a>]. Since reduced ejection fraction is a morphologic finding and not a diagnosis, is one among many measures of myocardial function and injury, and is an imprecise measure of LV function, the use of ejection fraction to make clinical decisions is controversial. (See <a class="local">'Limitations of classification by ejection fraction'</a> below.)</p><p></p><p class="headingAnchor" id="H3985635940"><span class="h1">LIMITATIONS OF CLASSIFICATION BY EJECTION FRACTION</span><span class="headingEndMark"> — </span>In patients with a known cause of HFmrEF, we typically refer to the disease by its cause (eg, anthracycline-induced cardiomyopathy) and use the LVEF to identify appropriate management that complements any disease-specific management (eg, cessation of alcohol for alcohol-induced cardiomyopathy). There is controversy concerning the extent to which HFmrEF is a distinct clinical entity. LVEF is not a robust measure of contractility [<a href="#rid3">3</a>], commonly changes over time [<a href="#rid4">4-6</a>], and varies by the method used. As discussed separately, there is only moderate correlation between different modalities for measuring LVEF, and the interobserver and intraobserver variability for measurement of LVEF are substantial (ranging up to nearly 20 percent). (See  <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">"Tests to evaluate left ventricular systolic function"</a>.)</p><p>In general, repeated measures of LV morphology are required to establish the presence of myocardial injury and assess the response to therapy. Similarly, correlation between cardiac findings (eg, LV volume, biventricular involvement) and noncardiac findings (eg, history of anthracycline exposure, laboratory tests) are required to establish the cause of injury. If the LVEF changes or discrepant LVEF values are detected by various imaging modalities, we suggest reviewing the studies with an imaging specialist to identify any technical limitation and to determine which results are most likely to be accurate.</p><p class="headingAnchor" id="H4194399413"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Among patients with HF, between 10 and 24 percent have an LVEF of 41 to 49 percent [<a href="#rid4">4,7-17</a>]. Patients with HFmrEF are more similar to patients with HF with reduced ejection fraction (HFrEF) than to those with HF with preserved ejection fraction (HFpEF) [<a href="#rid4">4,7-17</a>]. In particular, patients with HFmrEF have a relatively high prevalence of coronary artery disease (CAD) compared with patients with HFpEF [<a href="#rid7">7,12,15,16</a>].</p><p>The prognosis in patients with HFmrEF is described elsewhere in this topic. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H3620007153"><span class="h1">GENERAL MEASURES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Self-care</strong> – The approach to self-care in HFmrEF, including lifestyle modification, is the same as in other forms of HF, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults", section on 'HF self-management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of associated conditions</strong> – HFmrEF commonly presents with comorbid conditions that require management. Our approach to the management of these conditions is similar to that for patients with HFrEF and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Management of causes and associated conditions'</a>.)</p><p></p><p class="bulletIndent1">The approach to residual hypertension is discussed elsewhere in this topic. (See <a class="local">'Residual symptoms or hypertension'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial assessment</strong> – Patients with HFmrEF should be evaluated serially to assess clinical status, response to therapy, and need for changes in clinical management. At each visit, we obtain an interval history that includes an evaluation of symptoms during activities of daily living and at rest; medication tolerability and adherence; exposure to potential cardiotoxic agents including alcohol, tobacco, illicit drugs, and chemotherapeutic agents; and dietary intake of sodium and fluids. The approach to repeat echocardiography is similar to that for HFrEF. These issues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Follow-up and preventive care'</a>.)</p><p></p><p class="headingAnchor" id="H2091884078"><span class="h1">GOALS OF THERAPY</span><span class="headingEndMark"> — </span>In patients with HFmrEF, the goal of medical therapy is to reduce symptoms, decrease the risk of mortality or hospitalization, and either prevent further reduction in LVEF or promote improvement in LVEF.</p><p class="headingAnchor" id="H2839412004"><span class="h1">VOLUME OVERLOAD</span><span class="headingEndMark"> — </span>Patients with HFmrEF and volume overload require diuretic therapy to treat symptoms and maintain euvolemia. In general, we treat volume overload before starting long-term therapy, with the exception of therapies that may enhance diuresis in the volume overloaded state, such as sodium-glucose co-transporter 2 inhibitors [<a href="#rid18">18</a>]. A complete discussion of diuretic use in HF can be found separately. (See  <a class="medical medical_review" href="/z/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p class="headingAnchor" id="H4199936569"><span class="h1">APPROACH TO THERAPY</span></p><p class="headingAnchor" id="H802658099"><span class="h2">Disease-specific therapy</span><span class="headingEndMark"> — </span>In patients with HFmrEF with a known cause, appropriate treatment for the cause of HFmrEF is required. While many diseases can cause HFmrEF, common causes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary artery disease. (See  <a class="medical medical_review" href="/z/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mitral valve disease. (See  <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">"Chronic primary mitral regurgitation: Indications for intervention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aortic valve disease. (See  <a class="medical medical_review" href="/z/d/html/8154.html" rel="external">"Indications for valve replacement for high gradient aortic stenosis in adults", section on 'For symptomatic patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes. (See  <a class="medical medical_review" href="/z/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid disorders. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7853.html" rel="external">"Cardiovascular effects of hyperthyroidism", section on 'Heart failure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anthracycline-induced cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol-induced cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/3467.html" rel="external">"Alcohol-induced cardiomyopathy", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H2217996532"><span class="h2">Therapy for mildly reduced ejection fraction</span></p><p class="headingAnchor" id="H1890221899"><span class="h3">When to start?</span><span class="headingEndMark"> — </span>In most patients with newly diagnosed HFmrEF, we begin treatment without delay. However, in cases in which treating the cause of HFmrEF is expected to rapidly improve LV function (eg, surgery for severe valvular heart disease, revascularization for severe coronary artery disease), we may delay or modify the treatment regimen (eg, begin therapy after CAD revascularization, use only two agents) while disease-specific treatment begins.</p><p>In patients in whom disease-specific therapy (eg, thyroid replacement therapy) may slowly improve LV function over the course of months or if there is no clear response to disease-specific therapy (eg, coronary artery revascularization), we begin treatment.</p><p>This approach is based on our experience and the high efficacy of some disease-specific treatments. Diseases that may cause HFmrEF are listed elsewhere in this topic. (See <a class="local">'Disease-specific therapy'</a> above.)</p><p class="headingAnchor" id="H2186078893"><span class="h3">Combination therapy</span><span class="headingEndMark"> — </span>In patients with HFmrEF who have New York Heart Association (NYHA) class II to III HF symptoms  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>) despite optimal volume management, we suggest combination therapy with one agent from each of the following classes of medications rather than other combinations of therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin receptor blocker-neprilysin inhibitor (ARNI, ie, <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beta blocker</p><p class="bulletIndent1"><span class="glyph">●</span>Mineralocorticoid receptor antagonist (MRA)</p><p class="bulletIndent1"><span class="glyph">●</span>Sodium-glucose co-transporter 2 (SGLT2) inhibitor</p><p></p><p>The specific agents used for therapy are described in a table  (<a class="graphic graphic_table graphicRef140887" href="/z/d/graphic/140887.html" rel="external">table 3</a>). The management of the regimen of drugs used to treat HFmrEF, including order of therapy, target doses, alternatives to therapy, and adverse effects, is equivalent to the management of this regimen in patients with HF with reduced ejection fraction (HFrEF) and is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Regimen for patients with mild to moderate symptoms'</a>.)</p><p>Our approach to pharmacologic therapy in patients with HFmrEF is based on the efficacy of these drugs in patients with HFrEF and subgroup analyses of trials that studied their effects in HF with preserved ejection fraction (HFpEF); this indirect evidence has significant limitations (eg, multiple comparisons, unplanned analyses). Thus, the efficacy of these agents in patients with HFmrEF is less certain than in HFrEF, but the totality of evidence favors use.</p><p>Trials and studies that included patients with HFmrEF include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sacubitril-valsartan</strong> – The available evidence describes a possible benefit of <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> compared with other agents (ie, <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a>, <a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">valsartan</a>) used to treat HFrEF and HFpEF.</p><p></p><p class="bulletIndent1">In a pooled analysis of all patients enrolled in PARADIGM and PARAGON-HF trials, treatment with <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> was superior to <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a> or <a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">valsartan</a>, respectively; this effect was driven by benefit in patients with below normal LVEF [<a href="#rid19">19</a>]. However, within the cohort of patients with LVEF between 42.5 and 52.5 percent (n = 1427), the benefit of treatment with sacubitril-valsartan on total HF hospitalization and cardiovascular death was unclear (HR 0.81; 95% CI 0.64-1.03).</p><p></p><p class="bulletIndent1">The evidence on <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> treatment in HFrEF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Evidence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACE inhibitors and angiotensin receptor blockers</strong> – There is limited direct evidence of the effect of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in patients with HFmrEF:</p><p></p><p class="bulletIndent1">In an analysis from the CHARM Programme that included 1322 patients with HFmrEF, the time to HF hospitalization or cardiovascular death was significantly reduced by <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">candesartan</a> (7.4 versus 9.7 percent with placebo, hazard ratio [HR] 0.76, 95% CI 0.61-0.96) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">The evidence on ACE inhibitors and ARBs in the treatment of HFrEF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Evidence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> – For patients with HFmrEF, the evidence of beta blocker benefit is inferred from the benefits described in patients with HFrEF.</p><p></p><p class="bulletIndent1">In an individual patient data meta-analysis of 11 HF trials, beta blockers were shown to reduce all-cause and cardiovascular mortality compared with placebo across all LVEF strata below 50 percent [<a href="#rid21">21</a>]. For patients with HFmrEF, mortality was nonsignificantly lower with beta blocker treatment (7 versus 12 percent; HR 0.59, 95% CI 0.34-1.03) after a median of 1.3 years of treatment.</p><p></p><p class="bulletIndent1">The trial data on beta blockers in patients with HFrEF are described separately. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Evidence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mineralocorticoid receptor antagonists</strong> – The rationale for MRA use in patients with HFmrEF is largely extrapolated from the efficacy of these agents in patients with HFrEF.</p><p></p><p class="bulletIndent1">The effect of MRA treatment in patients with HFmrEF was evaluated in the TOPCAT trial, which enrolled patients with HF and LVEF ≥45 percent; patients with HFmrEF represented only a small fraction of the target population of patients with "HFpEF." The overall trial showed no clear benefit of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> compared with placebo [<a href="#rid22">22</a>]. Secondary analyses of this trial suggested that the effect of spironolactone was greater in patients with lower LVEF, but these analyses are not definitive [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1">The data on MRAs in patients with HFrEF are presented separately. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Evidence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SGLT2 inhibitors</strong> – Evidence supporting use of SGLT2 inhibitors in HFmrEF comes from large trials and indirectly from trials in patients with HFrEF. Approximately one-third of patients enrolled in the trials had an LVEF ≥40 and &lt;50 percent:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis that included patients with HFrEF and HFpEF, assignment to SGLT2 therapy was associated with a lower risk of HF hospitalization (HR 0.74, 95% CI 0.67-0.83) and a nonsignificant decrease in cardiovascular death (HR 0.88, 95% CI 0.77-1.00) compared with placebo [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In EMPEROR-Preserved, treatment with <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a> compared with placebo resulted in a reduction in HF hospitalization (9 versus 12 percent; HR 0.71, 95% CI 0.60-0.83) and a nonsignificant decrease in mortality (7 versus 8 percent; HR 0.91, 95% CI 0.76-1.09) [<a href="#rid25">25</a>]. In subgroup analyses, patients with HFmrEF had a treatment benefit that was similar to the benefit in the overall trial [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial (DELIVER) that included 10,418 patients with LVEF ≥40 percent, treatment with the SGLT2 inhibitor <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a> resulted in a lower risk of hospitalization compared with placebo (10.5 versus 13.3 percent; HR 0.77, 95% CI 0.67-0.89) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2">In a meta-analysis of trials that evaluated the effect of <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a> in a pooled analysis of patients with HFrEF, HFmrEF, and HFpEF, there was a mortality benefit associated with dapagliflozin treatment [<a href="#rid28">28</a>]. However, the mortality benefit of dapagliflozin was less certain in patients with an LVEF &gt;44 and ≤51 percent (cardiovascular death incidence 4.7 versus 5.2 percent in the placebo group; HR 0.91, 95% CI 0.69-1.2).</p><p></p><p class="bulletIndent1">The data on SGLT2 inhibitor use in HFrEF are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Evidence'</a>.)</p><p></p><p class="headingAnchor" id="H3371786870"><span class="h2">Residual symptoms or hypertension</span><span class="headingEndMark"> — </span>In patients with HFmrEF who take optimal medical therapy but have residual HF symptoms or hypertension, management depends on the patient’s characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Residual symptoms</strong> – In our experience, most optimally managed patients with HFmrEF have only mild HF symptoms. In patients with HFmrEF who have NYHA class II to III HF symptoms despite optimal combination therapy for HFmrEF, we reassess adherence and other reasons for failure of combination therapy (eg, dose optimization). (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Approach to persistent symptoms'</a>.)</p><p></p><p class="bulletIndent1">Additional agents studied in HFrEF include <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> and <a class="drug drug_general" data-topicid="130565" href="/z/d/drug information/130565.html" rel="external">vericiguat</a>, which have no clear benefit in this group of patients, as well as <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a>, which may reduce exercise capacity. Data show no clear effect of these agents or, in the case of ivabradine, possible harm:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Digoxin</strong> – Secondary analyses from the DIG trial showed that <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> did not clearly reduce HF hospitalizations in patients with HFmrEF (HR 0.80, 95% CI 0.63-1.03) and was less effective than for patients with HFrEF [<a href="#rid29">29</a>]. The details on the use of digoxin are the same as for patients with HFrEF, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ivabradine</strong> – In patients with HFmrEF, we avoid the use of <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a randomized trial in patients with HF and LVEF ≥45 percent, treatment with <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> had no discernable effect on six-minute walk distance (difference -3.8 m; 95% CI -19 to 11.6) and did not clearly improve natriuretic peptide levels or echocardiographic estimates of ventricular filling pressures [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a small crossover trial, <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> therapy was associated with lower peak oxygen consumption (VO<sub>2</sub>) compared with placebo (-2.1 versus 0.9 mL/kg/min, p = 0.003) [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vericiguat</strong> – <a class="drug drug_general" data-topicid="130565" href="/z/d/drug information/130565.html" rel="external">Vericiguat</a> has no clear benefit in patients with HFpEF:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a trial that included 789 patients with LVEF ≥45 percent and recent HF decompensation, <a class="drug drug_general" data-topicid="130565" href="/z/d/drug information/130565.html" rel="external">vericiguat</a> did not improve exercise tolerance compared with placebo after 24 weeks of observation [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a large trial that included patients with HF and LVEF &lt;45 percent, there was no clear benefit with <a class="drug drug_general" data-topicid="130565" href="/z/d/drug information/130565.html" rel="external">vericiguat</a> compared with placebo in a subgroup analysis of patients with LVEF &gt;40 and &lt;45 percent [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> — In patients who have residual hypertension after optimal therapy with the primary therapies for HFmrEF, options for therapy include <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> plus <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">isosorbide dinitrate</a>, hydralazine alone, or second-generation calcium channel blockers. These agents are less likely to cause harm than other antihypertensive agents, though it is reasonable to treat with other antihypertensive agents in select patients with intolerance to these agents.</p><p></p><p class="bulletIndent1">The approach to use of these agents in this population is similar to the approach in HFrEF, which is described separately. (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Add isosorbide dinitrate plus hydralazine in select patients'</a>.)</p><p></p><p class="bulletIndent1">The evidence on these agents in patients with HFmrEF is limited; the safety of these medications in patients with HFmrEF is largely inferred from their safety in patients with HFrEF:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hydralazine</strong><strong> plus </strong><strong>isosorbide dinitrate</strong> – Our approach to the use of these agents in HFmrEF extends from evidence in patients with HFrEF. The trials of <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> and <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> in HFrEF are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Renin-angiotensin/neprilysin blocker intolerance'</a> and  <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Add isosorbide dinitrate plus hydralazine in select patients'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Second-generation calcium channel blockers</strong> – While data are scant, second-generation dihydropyridine calcium channel blockers (eg, <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a>, <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a>) are likely safe in HFmrEF. Other calcium channel blockers should generally be avoided in patients with HFmrEF.</p><p></p><p class="bulletIndent2">The safety of these agents in patients with HFrEF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3455.html" rel="external">"Calcium channel blockers in heart failure with reduced ejection fraction"</a>.)</p><p></p><p class="headingAnchor" id="H141702560"><span class="h2">Changes in ejection fraction</span><span class="headingEndMark"> — </span>Among patients who present with HFmrEF, the LVEF may change over time:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improvement in LVEF</strong> – In patients whose LVEF improves with therapy for HFmrEF or disease-specific therapy, we continue appropriate treatment for HFmrEF, as discussed in this topic. This approach is based on limited data in patients with HFrEF, which are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Duration of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decline in LVEF</strong> – In patients with HFmrEF whose LVEF declines despite disease-specific or combination therapy for HFmrEF, additional therapy for HFrEF (eg, implantable cardioverter-defibrillator [ICD] placement) may be appropriate. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1689867958"><span class="h1">DEVICE THERAPY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Implantable cardioverter-defibrillators</strong> – Patients with HFmrEF and a history of sudden death or sustained ventricular arrhythmias should be managed according to standard recommendations for ICD use for secondary prevention of sudden cardiac death (SCD). In contrast to the body of evidence supporting ICD use for primary prevention of SCD in selected patients with HF with reduced ejection fraction, there is no evidence to support ICD therapy for primary prevention in patients with HFmrEF. (See  <a class="medical medical_review" href="/z/d/html/968.html" rel="external">"Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/946.html" rel="external">"Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac resynchronization therapy</strong> – For most patients with HFmrEF, the benefits of cardiac resynchronization therapy (CRT) are not likely to outweigh the risks. Indications for the use of CRT in selected patients with LVEF between 35 and 50 percent (eg, patients who are expected to require frequent ventricular pacing) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">"Cardiac resynchronization therapy in heart failure: Indications and choice of system", section on 'For patients with LVEF between 35 and 50 percent'</a> and  <a class="medical medical_review" href="/z/d/html/3493.html" rel="external">"Overview of pacemakers in heart failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive pulmonary artery pressure monitors </strong>– Our approach to the use of pulmonary artery pressure monitors in the management of HF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Device-based therapies'</a>.)</p><p></p><p class="headingAnchor" id="H24216444"><span class="h1">PROGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survival </strong>– Most evidence indicates that survival in patients with HFmrEF is better than in patients with HF with reduced ejection fraction (HFrEF) and either similar to or somewhat worse than what is observed in patients with HF with preserved ejection fraction (HFpEF) [<a href="#rid12">12,13,34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In-hospital mortality for patients with HFmrEF was shown to be 2.6 percent in an analysis from the Get with the Guidelines Registry, which was similar to that for patients with HFrEF and HFpEF [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the European Society of Cardiology Heart Failure Registry, one-year mortality was 7.6 percent in patients with HFmrEF, compared with 8.8 percent in patients with HFrEF and 6.4 percent in patients with HFpEF [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Over a median follow-up of 2.9 years in patients enrolled in the CHARM Programme, the rates of cardiovascular death or HF hospitalization were 15.9, 8.5, and 8.9 for patients with HFrEF, HFmrEF, and HFpEF, respectively [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Patients with improvement in LVEF from HFrEF to HFmrEF on medical therapy are likely to have a more favorable prognosis, while outcomes in those who deteriorate from HFpEF to HFmrEF are likely worse [<a href="#rid4">4,14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progression and recovery</strong> – It is not uncommon for LVEF to change over time in patients with HF. However, the data on progression and recovery of LVEF in patients with HFmrEF are unreliable.</p><p></p><p class="headingAnchor" id="H3644758137"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H2277438081"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Heart failure with mildly reduced ejection fraction (HFmrEF) is defined as the presence of clinical HF  (<a class="graphic graphic_table graphicRef55866" href="/z/d/graphic/55866.html" rel="external">table 1</a>) and a left ventricular ejection fraction (LVEF) of 41 to 49 percent. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – In patients with HFmrEF, the approach to self-care, management of associated conditions, and serial assessment is the same as for patients with HF with reduced ejection fraction (HFrEF). (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – In patients with HFmrEF, the goal of medical therapy is to reduce symptoms, decrease the risk of mortality, and either prevent further reduction in LVEF or promote improvement in LVEF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Volume overload</strong> – Patients with HFmrEF and volume overload require diuretic therapy to treat symptoms and maintain euvolemia. We treat volume overload before starting long-term therapy. (See  <a class="medical medical_review" href="/z/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disease-specific therapy</strong> – Patients with a known cause of HFmrEF require appropriate treatment for the cause of HFmrEF. While many diseases can cause HFmrEF, common causes include coronary artery disease (CAD), aortic stenosis, and toxin exposure. (See <a class="local">'Disease-specific therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Therapy for reduced ejection fraction</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>When to start pharmacologic therapy</strong> – In most patients with newly diagnosed HFmrEF, we begin treatment without delay. However, in cases in which treating the cause of HFmrEF is expected to rapidly improve LV function (eg, surgery for severe valvular heart disease), we may delay or modify the treatment regimen while disease-specific treatment begins.</p><p></p><p class="bulletIndent3">In patients in whom disease-specific therapy (eg, thyroid replacement therapy) may slowly improve LV function over the course of months or if there is no clear response to disease-specific therapy (eg, coronary artery revascularization), we begin treatment. (See <a class="local">'When to start?'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Combination therapy</strong> – For patients with HFmrEF with New York Heart Association (NYHA) class II to III symptoms  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 2</a>), we suggest combination therapy composed of <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a>, a beta blocker, a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose co-transporter 2 (SGLT2) inhibitor rather than other combinations of therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The specific components of combination therapy are contained in a table  (<a class="graphic graphic_table graphicRef140887" href="/z/d/graphic/140887.html" rel="external">table 3</a>). (See <a class="local">'Combination therapy'</a> above.)</p><p></p><p class="bulletIndent3">In patients who cannot tolerate <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">sacubitril-valsartan</a>, angiotensin converting enzyme (ACE) inhibitors or single-agent angiotensin II receptor blocker (ARB) therapy are acceptable alternatives for therapy  (<a class="graphic graphic_table graphicRef140887" href="/z/d/graphic/140887.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent3">In patients who cannot tolerate other components of primary therapy (eg, beta blockers, MRAs, SGLT2 inhibitors) there are no alternative agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Residual symptoms </strong>– In our experience, most optimally managed patients with HFmrEF have only mild HF symptoms. In patients with HFmrEF who have NYHA class II to III HF symptoms despite optimal combination therapy for HFmrEF, we reassess adherence and other reasons for failure of combination therapy (eg, dose optimization). (See <a class="local">'Residual symptoms or hypertension'</a> above.)</p><p></p><p class="bulletIndent2">Additional agents studied in HFrEF include <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> and <a class="drug drug_general" data-topicid="130565" href="/z/d/drug information/130565.html" rel="external">vericiguat</a>, which have no clear benefit in this group of patients, as well as <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a>, which may reduce exercise capacity. (See <a class="local">'Residual symptoms or hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Residual hypertension</strong> – In patients with HFmrEF who have residual hypertension after optimal therapy with the primary therapies for HFmrEF, options for therapy include <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a> plus <a class="drug drug_general" data-topicid="8580" href="/z/d/drug information/8580.html" rel="external">isosorbide dinitrate</a>, hydralazine monotherapy, or second-generation calcium channel blockers (eg, <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a>, <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>). (See <a class="local">'Residual symptoms or hypertension'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145:e895.</a></li><li><a class="nounderline abstract_t">Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129.</a></li><li><a class="nounderline abstract_t">Borlaug BA, Lam CS, Roger VL, et al. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54:410.</a></li><li><a class="nounderline abstract_t">Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail 2017; 19:1597.</a></li><li><a class="nounderline abstract_t">Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 2012; 5:720.</a></li><li><a class="nounderline abstract_t">Clarke CL, Grunwald GK, Allen LA, et al. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes 2013; 6:680.</a></li><li><a class="nounderline abstract_t">Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014; 168:721.</a></li><li><a class="nounderline abstract_t">Coles AH, Tisminetzky M, Yarzebski J, et al. Magnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings. J Am Heart Assoc 2015; 4.</a></li><li><a class="nounderline abstract_t">Kapoor JR, Kapoor R, Ju C, et al. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. JACC Heart Fail 2016; 4:464.</a></li><li><a class="nounderline abstract_t">Hsu JJ, Ziaeian B, Fonarow GC. Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. JACC Heart Fail 2017; 5:763.</a></li><li><a class="nounderline abstract_t">Nauta JF, Hummel YM, van Melle JP, et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Eur J Heart Fail 2017; 19:1569.</a></li><li><a class="nounderline abstract_t">Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19:1574.</a></li><li><a class="nounderline abstract_t">Koh AS, Tay WT, Teng THK, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 2017; 19:1624.</a></li><li><a class="nounderline abstract_t">Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017; 19:1258.</a></li><li><a class="nounderline abstract_t">Vedin O, Lam CSP, Koh AS, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circ Heart Fail 2017; 10.</a></li><li><a class="nounderline abstract_t">Rickenbacher P, Kaufmann BA, Maeder MT, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2017; 19:1586.</a></li><li><a class="nounderline abstract_t">Bhambhani V, Kizer JR, Lima JAC, et al. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur J Heart Fail 2018; 20:651.</a></li><li><a class="nounderline abstract_t">Packer M, Wilcox CS, Testani JM. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes. Circulation 2023; 148:354.</a></li><li><a class="nounderline abstract_t">Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation 2020; 141:352.</a></li><li><a class="nounderline abstract_t">Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018; 20:1230.</a></li><li><a class="nounderline abstract_t">Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018; 39:26.</a></li><li><a class="nounderline abstract_t">Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370:1383.</a></li><li><a class="nounderline abstract_t">Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016; 37:455.</a></li><li><a class="nounderline abstract_t">Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022; 400:757.</a></li><li><a class="nounderline abstract_t">Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451.</a></li><li><a class="nounderline abstract_t">Anker SD, Butler J, Usman MS, et al. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. Nat Med 2022; 28:2512.</a></li><li><a class="nounderline abstract_t">Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387:1089.</a></li><li><a class="nounderline abstract_t">Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 2022; 28:1956.</a></li><li><a class="nounderline abstract_t">Abdul-Rahim AH, Shen L, Rush CJ, et al. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur J Heart Fail 2018; 20:1139.</a></li><li><a class="nounderline abstract_t">Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 2017; 19:1495.</a></li><li><a class="nounderline abstract_t">Pal N, Sivaswamy N, Mahmod M, et al. Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction. Circulation 2015; 132:1719.</a></li><li><a class="nounderline abstract_t">Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA 2020; 324:1512.</a></li><li><a class="nounderline abstract_t">Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020; 382:1883.</a></li><li><a class="nounderline abstract_t">Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33:1750.</a></li></ol></div><div id="topicVersionRevision">Topic 117708 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363499" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27206819" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628115" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29024350" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22936826" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24129973" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Natural history of left ventricular ejection fraction in patients with heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25440801" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702084" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Magnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27256749" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032140" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29067761" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : What have we learned about heart failure with mid-range ejection fraction one year after its introduction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28386917" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28948683" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A comprehensive population-based characterization of heart failure with mid-range ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28370829" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28615366" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295985" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226491" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictors and outcomes of heart failure with mid-range ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37486998" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31736342" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29431256" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29040525" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24716680" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Spironolactone for heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26374849" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36041474" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34449189" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Empagliflozin in Heart Failure with a Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36471037" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36027570" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36030328" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29493058" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28462519" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26338956" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33079152" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222134" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21821849" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
